Abstract
The anti-plasmodial effects of alpha-onocerin (10, 30, 100, 300 mg/kg) and ART (1, 2, 4, 8, 16 mg/kg) were assessed in P. berghei-infected mice. Alpha-onocerin /ART were administered with a fixed dose combination of their median effective doses (ED50s) to determine the experimental ED50 (Zexp). An isobologram was developed to identify the nature of the interaction by comparing Zexp with the theoretical ED50 (Zadd).
Alpha-onocerin (300 mg/kg) showed a similar chemosuppression (93.51 ± 2.15%) to ART (2 mg/kg, i.p.) of 97.02 ± 0.27% in the 4-day suppressive test as well as in the prophylactic test with chemosuppression at 54.94% and 69.76% for alpha-onocerin (300 mg/kg) and artesunate (2 mg/kg, i.p.) respectively. All doses of alpha-onocerin significantly (p < 0.05) reduced pyrexia in 1 h and 2 h after their administration in the baker’s yeast test. ED50s for ART and alpha-onocerin were 1.33 ± 0.11 and 13.64 ± 0.22 mg/kg, respectively. The Zadd, Zexp and interaction index for alpha-onocerin /ART co-administration were 7.49 ± 3.46, 1.61 ± 0.78 and 0.22 respectively. The Zexp for alpha-onocerin /ART laid below the additive isobole indicating significant (p < 0.001) synergistic activity with ART.
Alpha-onocerin showed analgesic effects, antipyretic and synergistic anti-plasmodial effects in P. berghei-infected mice.
| Original language | English |
|---|---|
| Pages (from-to) | 735–746 |
| Number of pages | 12 |
| Journal | Advances in Traditional Medicine |
| Volume | 25 |
| Issue number | 3 |
| Early online date | 7 Jan 2025 |
| DOIs | |
| Publication status | Published - Sept 2025 |
Bibliographical note
Open Access via the SpringerNature AgreementWe like to acknowledge all the technicians in the Department of Pharmacology, KNUST.
Data Availability Statement
All data generated or analyzed during the study are included in this published article.Funding
The authors received no funding for this study.
Keywords
- anti-plasmodial
- alpha-onocerin
- combination therapy
- antimalarial
- Plasmodium berghei
Access to Document
- KwansahObresi_etal_ATM_In_Vivo_Anti-Plasmodial_VOR
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.